News Sentiment

URGN sentiment intelligence

UroGen Pharma Ltd news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 54 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 40.23 Week of 17 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

78/100 classification confidence.

Company focus 45

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+4.3% over one week, +19.8% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

URGN stock trades steady as UroGen revenue grows and pipeline advances

Market Reaction

Price moving ahead of tone

66/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 78/100 classification
One-week reaction 4.3% Price confirming higher
Trend fit Trend active 19.8% over four weeks
Fair value 140.8% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 32
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 45
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 11
Stock Titan 10
Investing.com 5
simplywall.st 5
TradingView 3
Sahm 3
Quartr 2
GuruFocus 2

Event Lens

What the news is about

Classified themes
Market update 26
Earnings 13
Analyst action 7
Regulatory and legal 6
Guidance 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-54 of 54
Stock Titan Direct company coverage

Affiliate files Form 144: UroGen (NASDAQ: URGN) sells two 10,000-share blocks

UroGen Pharma Ltd. (NASDAQ: URGN) had two 10,000-share blocks of common stock sold by an affiliate on May 8, 2026, and June 22, 2026, for $300,048 and $350,143, respectively. These dispositions were reported via a Form 144 filing and involved an affiliate, Mark Schoenberg, with R

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 20:00
Source
Stock Titan
Investing.com Direct company coverage

Urogen Pharma stock hits 52-week high at $39.59

Urogen Pharma (URGN) stock has reached a new 52-week high of $39.59, reflecting a 175% increase over the past year and strong investor confidence. Despite a 53% revenue surge and nearly 90% gross profit margins, InvestingPro analysis indicates the stock may be overvalued. Recent

Tone
Positive 71/100
Event
Earnings
Published
09 Jul 2026 19:00
Source
Investing.com